International clinical guideline for the management of classical galactosemia: diagnosis, treatment, and follow-up
- PMID: 27858262
- PMCID: PMC5306419
- DOI: 10.1007/s10545-016-9990-5
International clinical guideline for the management of classical galactosemia: diagnosis, treatment, and follow-up
Abstract
Classical galactosemia (CG) is an inborn error of galactose metabolism. Evidence-based guidelines for the treatment and follow-up of CG are currently lacking, and treatment and follow-up have been demonstrated to vary worldwide. To provide patients around the world the same state-of-the-art in care, members of The Galactosemia Network (GalNet) developed an evidence-based and internationally applicable guideline for the diagnosis, treatment, and follow-up of CG. The guideline was developed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. A systematic review of the literature was performed, after key questions were formulated during an initial GalNet meeting. The first author and one of the working group experts conducted data-extraction. All experts were involved in data-extraction. Quality of the body of evidence was evaluated and recommendations were formulated. Whenever possible recommendations were evidence-based, if not they were based on expert opinion. Consensus was reached by multiple conference calls, consensus rounds via e-mail and a final consensus meeting. Recommendations addressing diagnosis, dietary treatment, biochemical monitoring, and follow-up of clinical complications were formulated. For all recommendations but one, full consensus was reached. A 93 % consensus was reached on the recommendation addressing age at start of bone density screening. During the development of this guideline, gaps of knowledge were identified in most fields of interest, foremost in the fields of treatment and follow-up.
Conflict of interest statement
Compliance with ethical standardsConflict of interestAnnet M. Bosch is in receipt of research grants from Nutricia and was a member of an advisory board for Nutricia.Laurie E. Bernstein declares that she has no conflict of interest.Gerard T. Berry declares that he has no conflict of interest.Alberto B. Burlina declares that he has no conflict of interest.Francois Eyskens declares that he has no conflict of interest.Matthias Gautschi declares that he has no conflict of interest.Stephanie Grünewald declares that she has no conflict of interest.Cynthia S. Gubbels declares that she has no conflict of interest.Ina Knerr declares that she has no conflict of interest.Philippe Labrune declares that he has no conflict of interest.Johanna H. van der Lee declares that she has no conflict of interest.Anita MacDonald is in receipt of research grants from Nutricia and Vitaflo International, and is a member of the Nutricia IMD Advisory Board and Arla Advisory Board.Elaine Murphy is in receipt of clinical trial funding from Vitaflo and received travel support to attend meetings from Vitaflo.Katrin Õunap declares that she has no conflict of interest.Pat A. Portnoi received grants from Nutricia and Vitaflo to attend conferences, meetings or to give lectures in the past 5 years.Nancy L. Potter declares that she has no conflict of interest.M. Estela Rubio-Gozalbo declares that she has no conflict of interest.Jessica B. Spencer declares that she has no conflict of interest.Inge Timmers declares that she has no conflict of interest.Eileen P. Treacy declares that she has no conflict of interest.Sandra C. Van Calcar declares that she has no conflict of interest.Susan E. Waisbren declares that she has no conflict of interest.Lindsey Welling declares that she has no conflict of interest.Details of fundingThe initial GalNet meeting was financially supported by The Netherlands Organisation for Scientific Research (NWO; http://www.nwo.nl). The final consensus meeting was financially supported by the United States Galactosemia Foundation Inc. (patient organization; http://www.galactosemia.org/). The authors confirm independence from the sponsors; the content of the article has not been influenced by the sponsors.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
